InDex Pharmaceuticals announces expected cash balance per March 31, 2024
InDex Pharmaceuticals discontinues cobitolimod phase III program
STOCKHOLM, Oct. 20, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.
STOCKHOLM, Oct. 11, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that 30% of patients have completed the final visit in Induction Study 1 of the phase III program CONCLUDE, which is evaluating cobitolimod as a novel treatment for patients with moderate to severe, left-sided ulcerative colitis. The outcome of the cobitolimod dose selection analysis will be presented in Q4 this year according to plan.
STOCKHOLM, Oct. 5, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) will attend the United European Gastroenterology Week (UEGW), one of the world's leading gastroenterology congresses. UEGW is taking place October 14-17, 2023 in Copenhagen.
STOCKHOLM, Aug. 22, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the positive results from the pharmacokinetic (PK) study with cobitolimod in patients with moderate to severe ulcerative colitis will be presented at one of the leading gastroenterology conferences, the United European Gastroenterology Week (UEGW). The abstract was selected as one of the best abstracts for poster presentation and is therefore also chosen to be presented orally in one of the moderated poster sessions.
STOCKHOLM, Aug. 2, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that a new formulation patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides protection of the enema formulation of cobitolimod, that is currently under evaluation in the ongoing phase III program CONCLUDE.
Viatris is going after the ulcerative colitis market in Japan, inking a licensing agreement with Sweden’s InDex Pharmaceuticals to register and commercialize cobitolimod, a TLR9 agonist.
STOCKHOLM, May 31, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) will hold an investor call in light of today's press release announcing the company's license agreement. The investor call will take place on June 1, 2023 at 15:00 CET via MS Teams.